Expertise in
9
conditions

Enrico Cortesi

Policlinico Umberto I
Rome, IT 
Expertise in
9
conditions
Policlinico Umberto I
Rome, IT 

Overview

Enrico Cortesi practices practicing medicine in Rome, Italy.

Mr. Cortesi is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Lung Metastases, Colorectal Cancer, Renal Cell Carcinoma (RCC), HER-2 Positive Breast Cancer, and Orchiectomy.

He is actively involved in clinical research, co-authoring 213 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Policlinico Umberto I
Rome, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Phase II Trial of Metronomic Oral Vinorelbine Plus Cyclophosphamide and Capecitabine (VEX) Versus Weekly Paclitaxel as First-line or Second-line Treatment in Patients With ER-positive/HER2-negative Advanced or Metastatic Breast Cancer
A Randomized Phase II Trial of Metronomic Oral Vinorelbine Plus Cyclophosphamide and Capecitabine (VEX) Versus Weekly Paclitaxel as First-line or Second-line Treatment in Patients With ER-positive/HER2-negative Advanced or Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: February 26, 2024
Intervention Type: Drug
Study Drugs: Paclitaxel, Cyclophosphamide, Capecitabine, Vinorelbine
Study Phase: Phase 2
An Open-label, Randomized Phase III Study of Early Switch Maintenance vs DElayed Second-line Nivolumab in Advanced Stage Squamous Non Small-cell Lung Cancer (NSCLC) Patients After Standard First-line Platinum-based Chemotherapy - EDEN Trial
An Open-label, Randomized Phase III Study of Early Switch Maintenance vs DElayed Second-line Nivolumab in Advanced Stage Squamous Non Small-cell Lung Cancer (NSCLC) Patients After Standard First-line Platinum-based Chemotherapy - EDEN Trial
Enrollment Status: Unknown
Publish Date: October 03, 2022
Intervention Type: Other, Drug
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase II Randomized Trial Comparing a Combination of Abraxane and Gemcitabine Versus Gemcitabine Alone as First Line Treatment in Locally Advanced Unresectable Pancreatic Cancer. GAP (Gemcitabine Abraxane Pancreas) Trial
A Phase II Randomized Trial Comparing a Combination of Abraxane and Gemcitabine Versus Gemcitabine Alone as First Line Treatment in Locally Advanced Unresectable Pancreatic Cancer. GAP (Gemcitabine Abraxane Pancreas) Trial
Enrollment Status: Completed
Publish Date: October 09, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase III Study Of Low-Docetaxel Oxaliplatin, Capecitabine (Low-Tox) Vs Epirubicin, Oxaliplatin And Capecitabine (Eox) In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer
A Randomized Phase III Study Of Low-Docetaxel Oxaliplatin, Capecitabine (Low-Tox) Vs Epirubicin, Oxaliplatin And Capecitabine (Eox) In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer
Enrollment Status: Terminated
Publish Date: October 09, 2019
Intervention Type: Drug
Study Phase: Phase 3
A PHASE II SINGLE-ARM STUDY OF CETUXIMAB PLUS IRINOTECAN AS RECHALLENGE 3RD-LINE TREATMENT OF KRAS, NRAS AND BRAF WILD-TYPE IRINOTECAN-PRETREATED METASTATIC COLORECTAL CANCER PATIENTS PROGRESSING AFTER AN INITIAL RESPONSE TO A 1ST-LINE CETUXIMAB-CONTAINING THERAPY AND A STANDARD 2ND-LINE
A PHASE II SINGLE-ARM STUDY OF CETUXIMAB PLUS IRINOTECAN AS RECHALLENGE 3RD-LINE TREATMENT OF KRAS, NRAS AND BRAF WILD-TYPE IRINOTECAN-PRETREATED METASTATIC COLORECTAL CANCER PATIENTS PROGRESSING AFTER AN INITIAL RESPONSE TO A 1ST-LINE CETUXIMAB-CONTAINING THERAPY AND A STANDARD 2ND-LINE
Enrollment Status: Unknown
Publish Date: February 15, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

213 Total Publications

Evolution of Neo-RAS-WT in Circulating Tumor DNA from First-Line to Subsequent Therapies in Metastatic Colorectal Cancer.
Evolution of Neo-RAS-WT in Circulating Tumor DNA from First-Line to Subsequent Therapies in Metastatic Colorectal Cancer.
Journal: Cancers
Published: January 28, 2025

Frequently Asked Questions about Enrico Cortesi

Is Enrico Cortesi a top-rated expert for Lung Metastases?

MediFind is an objective health platform that identifies experts based on real-world data. Enrico Cortesi is classified as an Distinguished expert for Lung Metastases, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Enrico Cortesi participate in research or clinical trials?

Yes. Enrico Cortesi has published 213 articles and abstracts on conditions like Lung Metastases. You can view a list of Enrico Cortesi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cortesi's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile